{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T04:22:12Z","timestamp":1787458932496,"version":"build-2736575974"},"reference-count":207,"publisher":"MDPI AG","issue":"8","license":[{"start":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T00:00:00Z","timestamp":1787270400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Association de transfusion sanguine et de biog\u00e9n\u00e9tique Ga\u00e9tan Sale\u00fcn"},{"name":"Association Solidarit\u00e9 PLB Muco"},{"name":"Conseil r\u00e9gional de Bretagne"},{"id":[{"id":"https:\/\/ror.org\/05510z802","id-type":"ROR","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001665","name":"ANR-Agence Nationale de la Recherche","doi-asserted-by":"publisher","award":["ANR-23-CE18-0013-01"],"award-info":[{"award-number":["ANR-23-CE18-0013-01"]}],"id":[{"id":"10.13039\/501100001665","id-type":"DOI","asserted-by":"publisher"}]},{"award":["ANR-23-CE18-0013-01"],"award-info":[{"award-number":["ANR-23-CE18-0013-01"]}],"id":[{"id":"https:\/\/ror.org\/00rbzpz17","id-type":"ROR","asserted-by":"publisher"}]},{"name":"Fondation Groupama, Maladies rares"},{"name":"Minist\u00e8re de l\u2019Enseignement sup\u00e9rieur, de la Recherche et de l\u2019Innovation"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceutics"],"abstract":"<jats:p>Since the development of the first cystic fibrosis transmembrane conductance regulator (CFTR) modulator in 2012, these therapies have revolutionized patients\u2019 health. They are now the most effective treatment for people with cystic fibrosis (pwCF). In fact, elexacaftor\/tezacaftor\/ivacaftor and vanzacaftor\/tezacaftor\/deutivacaftor, the latest combination therapies consisting of a CFTR potentiator and two CFTR correctors, improved lung function by 14% in pwCF. Other modulator therapies targeting CFTR mRNA and\/or protein are currently under preclinical\/clinical investigation. However, due to the variant-specific nature of these therapies, about 10% of pwCF in Europe remains without effective treatment, and many treated pwCF experience various adverse events such as headaches, infections, hepatotoxicity, hypertension, and depression. Therefore, mutation-agnostic strategies such as gene therapy are needed. They could expand treatment eligibility for all pwCF and improve outcomes. In fact, nucleic acid delivery (e.g., pDNA, mRNA, oligonucleotides, genome editing) or targeting non-CFTR channels to restore ion transport represent promising future additional directions for CF therapy. This review aims to discuss a potential combination between gene therapy approaches and existing modulators to improve treatment eligibility, safety, and efficacy.<\/jats:p>","DOI":"10.3390\/pharmaceutics18081040","type":"journal-article","created":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T08:14:01Z","timestamp":1787300041000},"page":"1040","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Combining Gene Therapy with Current Modulator Treatments for Cystic Fibrosis: A Promising Area of Research"],"prefix":"10.3390","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-0954-1725","authenticated-orcid":false,"given":"Xavier","family":"Buin","sequence":"first","affiliation":[{"name":"UnivBrest, Inserm, EFS, UMR 1078, GGB, F-29200  Brest, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3336-6629","authenticated-orcid":false,"given":"Rosy","family":"Ghanem","sequence":"additional","affiliation":[{"name":"UnivBrest, Inserm, EFS, UMR 1078, GGB, F-29200  Brest, France"},{"name":"Service de G\u00e9n\u00e9tique M\u00e9dicale et de Biologie de la Reproduction, CHU de Brest, F-29200 Brest, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ines","family":"Pankonien","sequence":"additional","affiliation":[{"name":"BioISI\u2014Biosystems & Integrative Sciences Institute, Faculty of Sciences, University of Lisboa, Campo Grande, C8 bdg, 1749-016 Lisboa, Portugal"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fr\u00e9d\u00e9ric","family":"Becq","sequence":"additional","affiliation":[{"name":"Laboratoire PR\u00e9TI, University of Poitiers, F-86022 Poitiers, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0828-8630","authenticated-orcid":false,"given":"Margarida","family":"Amaral","sequence":"additional","affiliation":[{"name":"BioISI\u2014Biosystems & Integrative Sciences Institute, Faculty of Sciences, University of Lisboa, Campo Grande, C8 bdg, 1749-016 Lisboa, Portugal"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0452-6395","authenticated-orcid":false,"given":"Tristan","family":"Montier","sequence":"additional","affiliation":[{"name":"UnivBrest, Inserm, EFS, UMR 1078, GGB, F-29200  Brest, France"},{"name":"Service de G\u00e9n\u00e9tique M\u00e9dicale et de Biologie de la Reproduction, CHU de Brest, F-29200 Brest, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,8,21]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1016\/S0140-6736(20)32542-3","article-title":"Cystic fibrosis","volume":"397","author":"Shteinberg","year":"2021","journal-title":"Lancet"},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Lopes-Pacheco, M. (2020). CFTR Modulators: The Changing Face of Cystic Fibrosis in the Era of Precision Medicine. Front. Pharmacol., 10.","DOI":"10.3389\/fphar.2019.01662"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1002\/ppul.26954","article-title":"International disparities in diagnosis and treatment access for cystic fibrosis","volume":"59","author":"Guo","year":"2024","journal-title":"Pediatr. Pulmonol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"116468","DOI":"10.1016\/j.bcp.2024.116468","article-title":"ABC transporters involved in respiratory and cholestatic diseases: From rare to very rare monogenic diseases","volume":"229","author":"Lakli","year":"2024","journal-title":"Biochem. Pharmacol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.biocel.2014.01.024","article-title":"On the structural organization of the intracellular domains of CFTR","volume":"52","author":"Moran","year":"2014","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.biocel.2014.02.004","article-title":"CFTR structure and cystic fibrosis","volume":"52","author":"Cant","year":"2014","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1038\/s41586-023-05854-7","article-title":"CFTR function, pathology and pharmacology at single-molecule resolution","volume":"616","author":"Levring","year":"2023","journal-title":"Nature"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.1016\/S0140-6736(16)00576-6","article-title":"Cystic fibrosis","volume":"388","author":"Elborn","year":"2016","journal-title":"Lancet"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1016\/S0140-6736(23)01608-2","article-title":"The future of cystic fibrosis treatment: From disease mechanisms to novel therapeutic approaches","volume":"402","author":"Graeber","year":"2023","journal-title":"Lancet"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1016\/S2213-2600(16)00023-0","article-title":"Progress in therapies for cystic fibrosis","volume":"4","author":"Amaral","year":"2016","journal-title":"Lancet Respir. Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1016\/j.clinbiochem.2012.05.034","article-title":"Cystic fibrosis: Insight into CFTR pathophysiology and pharmacotherapy","volume":"45","author":"Lubamba","year":"2012","journal-title":"Clin. Biochem."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1186\/s12967-017-1193-9","article-title":"Cystic fibrosis: Current therapeutic targets and future approaches","volume":"15","author":"Rafeeq","year":"2017","journal-title":"J. Transl. Med."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1126\/science.1382316","article-title":"Regulation by ATP and ADP of CFTR chloride channels that contain mutant nucleotide-binding domains","volume":"257","author":"Anderson","year":"1992","journal-title":"Science"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.biocel.2014.02.023","article-title":"Genetics of cystic fibrosis: CFTR mutation classifications toward genotype-based CF therapies","volume":"52","author":"Fanen","year":"2014","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1172\/JCI6346","article-title":"Novel pharmacologic therapies for cystic fibrosis","volume":"103","author":"Zeitlin","year":"1999","journal-title":"J. Clin. Investig."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"21873","DOI":"10.1074\/jbc.274.31.21873","article-title":"C-terminal Truncations Destabilize the Cystic Fibrosis Transmembrane Conductance Regulator without Impairing Its Biogenesis: A NOVEL CLASS OF MUTATION*","volume":"274","author":"Haardt","year":"1999","journal-title":"J. Biol. Chem."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1164\/rccm.202402-0389CI","article-title":"Lentiviral Gene Therapy for Cystic Fibrosis: A Promising Approach and First-in-Human Trial","volume":"210","author":"Davies","year":"2024","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1016\/0092-8674(90)90148-8","article-title":"Defective intracellular transport and processing of CFTR is the molecular basis of most cystic fibrosis","volume":"63","author":"Cheng","year":"1990","journal-title":"Cell"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"ar15","DOI":"10.1091\/mbc.E23-08-0336","article-title":"Small-molecule correctors divert CFTR-F508del from ERAD by stabilizing sequential folding states","volume":"35","author":"Riepe","year":"2024","journal-title":"Mol. Biol. Cell"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1016\/S0140-6736(19)32597-8","article-title":"Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: A double-blind, randomised, phase 3 trial","volume":"394","author":"Heijerman","year":"2019","journal-title":"Lancet"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1038\/ng0994-42","article-title":"Administration of an adenovirus containing the human CFTR cDNA to the respiratory tract of individuals with cystic fibrosis","volume":"8","author":"Crystal","year":"1994","journal-title":"Nat. Genet."},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Cooney, A.L., McCray, P.B., and Sinn, P.L. (2018). Cystic Fibrosis Gene Therapy: Looking Back, Looking Forward. Genes, 9.","DOI":"10.3390\/genes9110538"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"3196","DOI":"10.1002\/1873-3468.70101","article-title":"Cystic fibrosis as a paradigmatic disease in bringing science to the bedside","volume":"599","author":"Amaral","year":"2025","journal-title":"FEBS Lett."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1016\/j.tibtech.2004.09.009","article-title":"Non-viral vectors in cystic fibrosis gene therapy: Progress and challenges","volume":"22","author":"Montier","year":"2004","journal-title":"Trends Biotechnol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"20","DOI":"10.32607\/actanaturae.11708","article-title":"Gene Therapy for Cystic Fibrosis: Recent Advances and Future Prospects","volume":"15","author":"Lomunova","year":"2023","journal-title":"Acta Nat."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"L1123","DOI":"10.1152\/ajplung.00049.2005","article-title":"Gene transfer of CFTR to airway epithelia: Low levels of expression are sufficient to correct Cl- transport and overexpression can generate basolateral CFTR","volume":"289","author":"Farmen","year":"2005","journal-title":"Am. J. Physiol. Lung Cell Mol. Physiol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"7375","DOI":"10.1038\/s41598-017-07504-1","article-title":"Correction of CFTR function in nasal epithelial cells from cystic fibrosis patients predicts improvement of respiratory function by CFTR modulators","volume":"7","author":"Pranke","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1513\/AnnalsATS.201708-668PS","article-title":"The U.S. Food and Drug Administration\u2019s Experience with Ivacaftor in Cystic Fibrosis. Establishing Efficacy Using In Vitro Data in Lieu of a Clinical Trial","volume":"15","author":"Durmowicz","year":"2018","journal-title":"Ann. Am. Thorac. Soc."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1089\/hum.2007.022","article-title":"Repeated aerosolized AAV-CFTR for treatment of cystic fibrosis: A randomized placebo-controlled phase 2B trial","volume":"18","author":"Moss","year":"2007","journal-title":"Hum. Gene Ther."},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Fischer, M.D., Simonelli, F., Sahni, J., Holz, F.G., Maier, R., Fasser, C., Suhner, A., Stiehl, D.P., Chen, B., and Audo, I. (2024). Real-World Safety and Effectiveness of Voretigene Neparvovec: Results up to 2 Years from the Prospective, Registry-Based PERCEIVE Study. Biomolecules, 14.","DOI":"10.3390\/biom14010122"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1089\/hum.2024.063","article-title":"SP-101, A Novel Adeno-Associated Virus Gene Therapy for the Treatment of Cystic Fibrosis, Mediates Functional Correction of Primary Human Airway Epithelia from Donors with Cystic Fibrosis","volume":"35","author":"Excoffon","year":"2024","journal-title":"Hum. Gene Ther."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"S11","DOI":"10.1016\/S1569-1993(24)00140-1","article-title":"WS06.01 CFTR transgene expression in airway epithelial cells following aerosolized administration of the AAV-based gene therapy 4D-710 to adults with cystic fibrosis lung disease","volume":"23","author":"Mermis","year":"2024","journal-title":"J. Cyst. Fibros."},{"key":"ref_33","first-page":"A1043","article-title":"Identification and Characterization of a Novel AAV Capsid and Product for the Treatment of Cystic Fibrosis","volume":"203","author":"Calton","year":"2021","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1165\/rcmb.2025-0243MA","article-title":"Design and characterization of 4D-710, an aerosolized gene therapy for cystic fibrosis lung disease","volume":"74","author":"Calton","year":"2026","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Marquez Loza, L.I., Yuen, E.C., and McCray, P.B. (2019). Lentiviral Vectors for the Treatment and Prevention of Cystic Fibrosis Lung Disease. Genes, 10.","DOI":"10.3390\/genes10030218"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1136\/thoraxjnl-2016-208406","article-title":"Preparation for a first-in-man lentivirus trial in patients with cystic fibrosis","volume":"72","author":"Alton","year":"2017","journal-title":"Thorax"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"2301683","DOI":"10.1183\/13993003.01683-2023","article-title":"Pharmacological and pre-clinical safety profile of rSIV.F\/HN, a hybrid lentiviral vector for cystic fibrosis gene therapy","volume":"65","author":"Moiseenko","year":"2024","journal-title":"Eur. Respir. J."},{"key":"ref_38","first-page":"A6351","article-title":"Evaluation of KB407, An HSV-1-Based Gene Therapy Vector for the Treatment of Cystic Fibrosis, in Healthy and Patient-Derived Airway Cells Including an Apical-out Diseased Airway Organoid Model","volume":"209","author":"Artusi","year":"2024","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1016\/S2213-2600(15)00245-3","article-title":"Repeated nebulisation of non-viral CFTR gene therapy in patients with cystic fibrosis: A randomised, double-blind, placebo-controlled, phase 2b trial","volume":"3","author":"Alton","year":"2015","journal-title":"Lancet Respir. Med."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1038\/nbt1399","article-title":"CpG-free plasmids confer reduced inflammation and sustained pulmonary gene expression","volume":"26","author":"Hyde","year":"2008","journal-title":"Nat. Biotechnol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/j.jconrel.2025.01.017","article-title":"The (re)emergence of aerosol delivery: Treatment of pulmonary diseases and its clinical challenges","volume":"379","author":"Ghanem","year":"2025","journal-title":"J. Control. Release"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"114416","DOI":"10.1016\/j.addr.2022.114416","article-title":"The role of lipid components in lipid nanoparticles for vaccines and gene therapy","volume":"188","author":"Kulkarni","year":"2022","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"S19","DOI":"10.1016\/S1569-1993(24)00166-8","article-title":"WS10.03 Inhaled LUNAR\u00ae-CFTR mRNA (ARCT-032) is safe and well-tolerated: A phase 1 study","volume":"23","author":"Geller","year":"2024","journal-title":"J. Cyst. Fibros."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1038\/s41565-020-0669-6","article-title":"Selective organ targeting (SORT) nanoparticles for tissue-specific mRNA delivery and CRISPR\u2013Cas gene editing","volume":"15","author":"Cheng","year":"2020","journal-title":"Nat. Nanotechnol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1016\/j.jcf.2023.04.008","article-title":"Inhaled mRNA therapy for treatment of cystic fibrosis: Interim results of a randomized, double-blind, placebo-controlled phase 1\/2 clinical study","volume":"22","author":"Rowe","year":"2023","journal-title":"J. Cyst. Fibros."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1038\/s41587-022-01294-2","article-title":"The clinical progress of mRNA vaccines and immunotherapies","volume":"40","author":"Barbier","year":"2022","journal-title":"Nat. Biotechnol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"122853","DOI":"10.1016\/j.biomaterials.2024.122853","article-title":"Pharmaceutical strategies for optimized mRNA expression","volume":"314","author":"Shi","year":"2025","journal-title":"Biomaterials"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"2034","DOI":"10.1016\/j.ymthe.2018.05.014","article-title":"Lipid Nanoparticle-Delivered Chemically Modified mRNA Restores Chloride Secretion in Cystic Fibrosis","volume":"26","author":"Robinson","year":"2018","journal-title":"Mol. Ther."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"10","DOI":"10.14348\/molcells.2023.2172","article-title":"Antisense Oligonucleotide Therapeutics for Cystic Fibrosis: Recent Developments and Perspectives","volume":"46","author":"Kim","year":"2023","journal-title":"Mol. Cells"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"2344","DOI":"10.1038\/s41467-022-29935-9","article-title":"CFTR mRNAs with nonsense codons are degraded by the SMG6-mediated endonucleolytic decay pathway","volume":"13","author":"Sanderlin","year":"2022","journal-title":"Nat. Commun."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1074\/jbc.M116.764720","article-title":"Correctors and Potentiators Rescue Function of the Truncated W1282X-Cystic Fibrosis Transmembrane Regulator (CFTR) Translation Product","volume":"292","author":"Haggie","year":"2017","journal-title":"J. Biol. Chem."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1089\/nat.2023.0015","article-title":"Delivery Characterization of SPL84 Inhaled Antisense Oligonucleotide Drug for 3849 + 10 kb C- > T Cystic Fibrosis Patients","volume":"33","author":"Friedman","year":"2023","journal-title":"Nucleic Acid Ther."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"S10","DOI":"10.1016\/S1569-1993(24)00137-1","article-title":"WS05.04 SPL84 efficient and durable effect, restoring 3849 +10 kb C-to-T mutated CFTR, when treated through the apical side of primary HBE cells","volume":"23","author":"Galai","year":"2024","journal-title":"J. Cyst. Fibros."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.jcf.2024.10.004","article-title":"A phase I study assessing the safety and tolerability of SPL84, an inhaled antisense oligonucleotide for treatment of cystic fibrosis patients with the 3849 +10kb C->T","volume":"24","author":"Caraco","year":"2025","journal-title":"J. Cyst. Fibros."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"2978","DOI":"10.1038\/s41467-022-30668-y","article-title":"Gene-specific nonsense-mediated mRNA decay targeting for cystic fibrosis therapy","volume":"13","author":"Kim","year":"2022","journal-title":"Nat. Commun."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"100416","DOI":"10.1016\/j.jbc.2021.100416","article-title":"Antisense technology: A review","volume":"296","author":"Crooke","year":"2021","journal-title":"J. Biol. Chem."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/bs.pmbts.2020.12.018","article-title":"Rewriting CFTR to cure cystic fibrosis","volume":"182","author":"Maule","year":"2021","journal-title":"Prog. Mol. Biol. Transl. Sci."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"4091","DOI":"10.1016\/j.ymthe.2025.06.021","article-title":"CRISPR for cystic fibrosis: Advances and insights from a systematic review","volume":"33","author":"Nicosia","year":"2025","journal-title":"Mol. Ther."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1038\/s41586-019-1711-4","article-title":"Search-and-replace genome editing without double-strand breaks or donor DNA","volume":"576","author":"Anzalone","year":"2019","journal-title":"Nature"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"e202000940","DOI":"10.26508\/lsa.202000940","article-title":"Evaluating CRISPR-based prime editing for cancer modeling and CFTR repair in organoids","volume":"4","author":"Geurts","year":"2021","journal-title":"Life Sci. Alliance"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"7322","DOI":"10.1038\/s41467-023-42948-2","article-title":"Lung SORT LNPs enable precise homology-directed repair mediated CRISPR\/Cas genome correction in cystic fibrosis models","volume":"14","author":"Wei","year":"2023","journal-title":"Nat. Commun."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"C1222","DOI":"10.1152\/ajpcell.00362.2010","article-title":"Role of epithelial HCO3\u2212 transport in mucin secretion: Lessons from cystic fibrosis","volume":"299","author":"Quinton","year":"2010","journal-title":"Am. J. Physiol. Cell Physiol."},{"key":"ref_63","doi-asserted-by":"crossref","unstructured":"Hanssens, L.S., Duchateau, J., and Casimir, G.J. (2021). CFTR Protein: Not Just a Chloride Channel?. Cells, 10.","DOI":"10.3390\/cells10112844"},{"key":"ref_64","doi-asserted-by":"crossref","unstructured":"Huang, Y., Zhang, J., Wang, X., Jing, H., and Li, H. (2024). Aerosol Inhalation of Gene Delivery Therapy for Pulmonary Diseases. Biomolecules, 14.","DOI":"10.3390\/biom14080904"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1089\/humc.2014.019","article-title":"Aerosol delivery of DNA\/liposomes to the lung for cystic fibrosis gene therapy","volume":"25","author":"Davies","year":"2014","journal-title":"Hum. Gene Ther. Clin. Dev."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1038\/s41586-018-0394-6","article-title":"A single-cell atlas of the airway epithelium reveals the CFTR-rich pulmonary ionocyte","volume":"560","author":"Plasschaert","year":"2018","journal-title":"Nature"},{"key":"ref_67","doi-asserted-by":"crossref","unstructured":"Scudieri, P., Musante, I., Venturini, A., Guidone, D., Genovese, M., Cresta, F., Caci, E., Palleschi, A., Poeta, M., and Santamaria, F. (2020). Ionocytes and CFTR Chloride Channel Expression in Normal and Cystic Fibrosis Nasal and Bronchial Epithelial Cells. Cells, 9.","DOI":"10.3390\/cells9092090"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1164\/rccm.202309-1565OC","article-title":"Pulmonary Ionocytes Regulate Airway Surface Liquid pH in Primary Human Bronchial Epithelial Cells","volume":"210","author":"Luan","year":"2024","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_69","doi-asserted-by":"crossref","unstructured":"Allan, K.M., Zhang, S., Wong, S.L., Capraro, A., McCarron, A., Skinner, D., Kardia, E., Zheng, Y., Zhong, L., and Ng, C.-A. (2025). Gene-Corrected Basal Cells Restore CFTR In Vitro; Transplants Regenerate Epithelium in a Preclinical Sinus Model. bioRxiv.","DOI":"10.1101\/2025.07.21.666023"},{"key":"ref_70","doi-asserted-by":"crossref","unstructured":"Durymanov, M., and Reineke, J. (2018). Non-viral Delivery of Nucleic Acids: Insight into Mechanisms of Overcoming Intracellular Barriers. Front. Pharmacol., 9.","DOI":"10.3389\/fphar.2018.00971"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"101244","DOI":"10.1016\/j.omtm.2024.101244","article-title":"Durable transgene expression and efficient re-administration after rAAV2.5T-mediated fCFTR\u0394R gene delivery to adult ferret lungs","volume":"32","author":"Tang","year":"2024","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1080\/17435889.2026.2640157","article-title":"Inhalable gene and RNA therapy for cystic fibrosis: Perspectives and progress in clinical development","volume":"21","author":"Munir","year":"2026","journal-title":"Nanomedicine"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1542\/peds.101.6.1013","article-title":"Incidence and prevalence of neutralizing antibodies to the common adenoviruses in children with cystic fibrosis: Implication for gene therapy with adenovirus vectors","volume":"101","author":"Piedra","year":"1998","journal-title":"Pediatrics"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1378\/chest.125.2.509","article-title":"Repeated Adeno-Associated Virus Serotype 2 Aerosol-Mediated Cystic Fibrosis Transmembrane Regulator Gene Transfer to the Lungs of Patients with Cystic Fibrosis: A Multicenter, Double-Blind, Placebo-Controlled Trial","volume":"125","author":"Moss","year":"2004","journal-title":"Chest"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1136\/archdischild-2012-302158","article-title":"Gene therapy in cystic fibrosis","volume":"99","author":"Armstrong","year":"2014","journal-title":"Arch. Dis. Child."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"102759","DOI":"10.1016\/j.omtn.2025.102759","article-title":"Genetic strategies for therapy of Duchenne muscular dystrophy","volume":"36","author":"Chamberlain","year":"2025","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"e2418731122","DOI":"10.1073\/pnas.2418731122","article-title":"Systemic in utero gene editing as a treatment for cystic fibrosis","volume":"122","author":"Ricciardi","year":"2025","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"L737","DOI":"10.1152\/ajplung.00022.2026","article-title":"Considerations for early life genetic therapies in cystic fibrosis","volume":"330","author":"Cooney","year":"2026","journal-title":"Am. J. Physiol. Lung Cell. Mol. Physiol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1136\/jme.2005.012740","article-title":"Gene therapy for children with cystic fibrosis\u2014Who has the right to choose?","volume":"32","author":"Prasad","year":"2006","journal-title":"J. Med. Ethics"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"101788","DOI":"10.1016\/j.bpg.2022.101788","article-title":"Digestive outcomes in Cystic fibrosis","volume":"56\u201357","author":"Ley","year":"2022","journal-title":"Best. Pract. Res. Clin. Gastroenterol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"19748","DOI":"10.1038\/s41598-022-24374-4","article-title":"Survival of people with cystic fibrosis in Australia","volume":"12","author":"Ruseckaite","year":"2022","journal-title":"Sci. Rep."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1007\/s41030-025-00303-4","article-title":"Impact of CFTR Modulators on Longitudinal Cystic Fibrosis Survival and Mortality: Review and Secondary Analysis","volume":"11","author":"Rubin","year":"2025","journal-title":"Pulm. Ther."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1056\/NEJMoa1409547","article-title":"Lumacaftor\u2013Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del CFTR","volume":"373","author":"Wainwright","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1164\/rccm.201301-0153OC","article-title":"Efficacy and Safety of Ivacaftor in Patients Aged 6 to 11 Years with Cystic Fibrosis with a G551D Mutation","volume":"187","author":"Davies","year":"2013","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/S2213-2600(24)00411-9","article-title":"Vanzacaftor\u2013tezacaftor\u2013deutivacaftor versus elexacaftor\u2013tezacaftor\u2013ivacaftor in individuals with cystic fibrosis aged 12 years and older (SKYLINE Trials VX20-121-102 and VX20-121-103): Results from two randomised, active-controlled, phase 3 trials","volume":"13","author":"Keating","year":"2025","journal-title":"Lancet Respir. Med."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1126\/science.aaw7611","article-title":"Structural identification of a hotspot on CFTR for potentiation","volume":"364","author":"Liu","year":"2019","journal-title":"Science"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.cell.2021.12.009","article-title":"Mechanism of CFTR correction by type I folding correctors","volume":"185","author":"Fiedorczuk","year":"2022","journal-title":"Cell"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1126\/science.ade2216","article-title":"Molecular Structures Reveal Synergistic Rescue of \u0394508 CFTR by Trikafta Modulators","volume":"378","author":"Fiedorczuk","year":"2022","journal-title":"Science"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"2564","DOI":"10.1172\/JCI24898","article-title":"Small-molecule correctors of defective \u0394F508-CFTR cellular processing identified by high-throughput screening","volume":"115","author":"Pedemonte","year":"2005","journal-title":"J. Clin. Investig."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"L1117","DOI":"10.1152\/ajplung.00169.2005","article-title":"Rescue of DeltaF508-CFTR trafficking and gating in human cystic fibrosis airway primary cultures by small molecules","volume":"290","author":"Straley","year":"2006","journal-title":"Am. J. Physiol. Lung Cell Mol. Physiol."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"18825","DOI":"10.1073\/pnas.0904709106","article-title":"Rescue of CF airway epithelial cell function in vitro by a CFTR potentiator, VX-770","volume":"106","author":"Hadida","year":"2009","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_92","doi-asserted-by":"crossref","unstructured":"Baroni, D. (2025). Unraveling the Mechanism of Action, Binding Sites, and Therapeutic Advances of CFTR Modulators: A Narrative Review. Curr. Issues Mol. Biol., 47.","DOI":"10.3390\/cimb47020119"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1056\/NEJMoa1709846","article-title":"Tezacaftor\u2013Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del","volume":"377","author":"Munck","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_94","doi-asserted-by":"crossref","unstructured":"Gramegna, A., Contarini, M., Aliberti, S., Casciaro, R., Blasi, F., and Castellani, C. (2020). From Ivacaftor to Triple Combination: A Systematic Review of Efficacy and Safety of CFTR Modulators in People with Cystic Fibrosis. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21165882"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1085\/jgp.111.3.477","article-title":"Actions of genistein on cystic fibrosis transmembrane conductance regulator channel gating. Evidence for two binding sites with opposite effects","volume":"111","author":"Wang","year":"1998","journal-title":"J. Gen. Physiol."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"102542","DOI":"10.1016\/j.isci.2021.102542","article-title":"Identification of binding sites for ivacaftor on the cystic fibrosis transmembrane conductance regulator","volume":"24","author":"Laselva","year":"2021","journal-title":"iScience"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"3712","DOI":"10.1016\/j.cell.2024.04.046","article-title":"Structure-based discovery of CFTR potentiators and inhibitors","volume":"187","author":"Liu","year":"2024","journal-title":"Cell"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1085\/jgp.201912360","article-title":"Identifying the molecular target sites for CFTR potentiators GLPG1837 and VX-770","volume":"151","author":"Yeh","year":"2019","journal-title":"J. Gen. Physiol."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"RP88659","DOI":"10.7554\/eLife.88659.3","article-title":"Computational analysis of long-range allosteric communications in CFTR","volume":"12","author":"Ersoy","year":"2023","journal-title":"eLife"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/j.jcf.2021.03.011","article-title":"Elexacaftor co-potentiates the activity of F508del and gating mutants of CFTR","volume":"20","author":"Veit","year":"2021","journal-title":"J. Cyst. Fibros."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"19810","DOI":"10.1038\/s41598-021-99184-1","article-title":"Elexacaftor is a CFTR potentiator and acts synergistically with ivacaftor during acute and chronic treatment","volume":"11","author":"Shaughnessy","year":"2021","journal-title":"Sci. Rep."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"17640","DOI":"10.1038\/s41598-019-54158-2","article-title":"Nanomolar-potency \u2018co-potentiator\u2019 therapy for cystic fibrosis caused by a defined subset of minimal function CFTR mutants","volume":"9","author":"Phuan","year":"2019","journal-title":"Sci. Rep."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1124\/jpet.117.241497","article-title":"Altering Metabolic Profiles of Drugs by Precision Deuteration 2: Discovery of a Deuterated Analog of Ivacaftor with Differentiated Pharmacokinetics for Clinical Development","volume":"362","author":"Harbeson","year":"2017","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1080\/14656566.2025.2538275","article-title":"Advancing cystic fibrosis treatment: Investigational agents on the horizon","volume":"26","author":"Santos","year":"2025","journal-title":"Expert. Opin. Pharmacother."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"S62","DOI":"10.1016\/j.jcf.2025.03.654","article-title":"EPS7.07Safety assessment of the FAIR therapeutics CFTR modulators nesolicaftor, posenacaftor and dirocaftor in CF patients","volume":"24","author":"Cipriani","year":"2025","journal-title":"J. Cyst. Fibros."},{"key":"ref_106","doi-asserted-by":"crossref","unstructured":"Gees, M., Musch, S., Van der Plas, S., Wesse, A.-S., Vandevelde, A., Verdonck, K., Mammoliti, O., Hwang, T.-C., Sonck, K., and Stouten, P. (2018). Identification and Characterization of Novel CFTR Potentiators. Front. Pharmacol., 9.","DOI":"10.3389\/fphar.2018.01221"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1164\/rccm.202303-0458OC","article-title":"Icenticaftor, a CFTR Potentiator, in COPD: A Multicenter, Parallel-Group, Double-Blind Clinical Trial","volume":"208","author":"Martinez","year":"2023","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.jcf.2020.11.002","article-title":"Safety and efficacy of the cystic fibrosis transmembrane conductance regulator potentiator icenticaftor (QBW251)","volume":"20","author":"Kazani","year":"2021","journal-title":"J. Cyst. Fibros."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/00368504251384892","article-title":"Implications for cystic fibrosis therapy: Potentiator icenticaftor is superior to ivacaftor in improving function and maintaining stability of F508del CFTR","volume":"108","author":"Cholon","year":"2025","journal-title":"Sci. Prog."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"246ra97","DOI":"10.1126\/scitranslmed.3008889","article-title":"Some gating potentiators, including VX-770, diminish \u0394F508-CFTR functional expression","volume":"6","author":"Veit","year":"2014","journal-title":"Sci. Transl. Med."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"e187951","DOI":"10.1172\/jci.insight.187951","article-title":"The potentiator ivacaftor is essential for pharmacological restoration of F508del-CFTR function and mucociliary clearance in cystic fibrosis","volume":"10","author":"Rubil","year":"2025","journal-title":"JCI Insight"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1038\/nchembio.1253","article-title":"Mechanism-based corrector combination restores \u0394F508-CFTR folding and function","volume":"9","author":"Okiyoneda","year":"2013","journal-title":"Nat. Chem. Biol."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"eadk1814","DOI":"10.1126\/sciadv.adk1814","article-title":"A uniquely efficacious type of CFTR corrector with complementary mode of action","volume":"10","author":"Marchesin","year":"2024","journal-title":"Sci. Adv."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/S2213-2600(14)70132-8","article-title":"A CFTR corrector (lumacaftor) and a CFTR potentiator (ivacaftor) for treatment of patients with cystic fibrosis who have a phe508del CFTR mutation: A phase 2 randomised controlled trial","volume":"2","author":"Boyle","year":"2014","journal-title":"Lancet Respir. Med."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1096\/fj.12-216119","article-title":"Correctors of \u0394F508 CFTR restore global conformational maturation without thermally stabilizing the mutant protein","volume":"27","author":"He","year":"2013","journal-title":"FASEB J."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1002\/cbic.201500123","article-title":"Capturing the direct binding of CFTR correctors to CFTR using click chemistry","volume":"16","author":"Sinha","year":"2015","journal-title":"Chembiochem"},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1056\/NEJMoa1807120","article-title":"VX-445-Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles","volume":"379","author":"Keating","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1164\/rccm.201704-0717OC","article-title":"Tezacaftor\/Ivacaftor in Subjects with Cystic Fibrosis and F508del\/F508del-CFTR or F508del\/G551D-CFTR","volume":"197","author":"Donaldson","year":"2018","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"166955","DOI":"10.1016\/j.jmb.2021.166955","article-title":"Co-Translational Folding of the First Transmembrane Domain of ABC-Transporter CFTR is Supported by Assembly with the First Cytosolic Domain","volume":"433","author":"Kleizen","year":"2021","journal-title":"J. Mol. Biol."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa1908639","article-title":"Elexacaftor\u2013Tezacaftor\u2013Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele","volume":"381","author":"Polineni","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_121","first-page":"192","article-title":"Elexacaftor-Tezacaftor-Ivacaftor: The First Triple-Combination Cystic Fibrosis Transmembrane Conductance Regulator Modulating Therapy","volume":"25","author":"Ridley","year":"2020","journal-title":"J. Pediatr. Pharmacol. Ther."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"e139983","DOI":"10.1172\/jci.insight.139983","article-title":"Allosteric folding correction of F508del and rare CFTR mutants by elexacaftor-tezacaftor-ivacaftor (Trikafta) combination","volume":"5","author":"Veit","year":"2020","journal-title":"JCI Insight"},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1186\/s13023-022-02350-5","article-title":"The impact of FDA and EMA regulatory decision-making process on the access to CFTR modulators for the treatment of cystic fibrosis","volume":"17","author":"Costa","year":"2022","journal-title":"Orphanet J. Rare Dis."},{"key":"ref_124","doi-asserted-by":"crossref","unstructured":"Veit, G., Velkov, T., Xu, H., Vadeboncoeur, N., Bilodeau, L., Matouk, E., and Lukacs, G.L. (2021). A Precision Medicine Approach to Optimize Modulator Therapy for Rare CFTR Folding Mutants. J. Pers. Med., 11.","DOI":"10.3390\/jpm11070643"},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"2100671","DOI":"10.1183\/13993003.00671-2021","article-title":"The rescue of F508del-CFTR by elexacaftor\/tezacaftor\/ivacaftor (Trikafta) in human airway epithelial cells is underestimated due to the presence of ivacaftor","volume":"59","author":"Becq","year":"2022","journal-title":"Eur. Respir. J."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s00018-022-04671-x","article-title":"ABC-transporter CFTR folds with high fidelity through a modular, stepwise pathway","volume":"80","author":"Im","year":"2023","journal-title":"Cell Mol. Life Sci."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"176390","DOI":"10.1016\/j.ejphar.2024.176390","article-title":"PTI-801 (posenacaftor) shares a common mechanism with VX-445 (elexacaftor) to rescue p.Phe508del-CFTR","volume":"967","author":"Ferreira","year":"2024","journal-title":"Eur. J. Pharmacol."},{"key":"ref_128","doi-asserted-by":"crossref","unstructured":"de Wilde, G., Gees, M., Musch, S., Verdonck, K., Jans, M., Wesse, A.-S., Singh, A.K., Hwang, T.-C., Christophe, T., and Pizzonero, M. (2019). Identification of GLPG\/ABBV-2737, a Novel Class of Corrector, Which Exerts Functional Synergy with Other CFTR Modulators. Front. Pharmacol., 10.","DOI":"10.3389\/fphar.2019.00514"},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"5216","DOI":"10.1021\/acs.jmedchem.3c01790","article-title":"Discovery of GLPG2737, a Potent Type 2 Corrector of CFTR for the Treatment of Cystic Fibrosis in Combination with a Potentiator and a Type 1 Co-corrector","volume":"67","author":"Pizzonero","year":"2024","journal-title":"J. Med. Chem."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1021\/acs.jmedchem.7b01339","article-title":"Discovery of 4-[(2R,4R)-4-({[1-(2,2-Difluoro-1,3-benzodioxol-5-yl)cyclopropyl]carbonyl}amino)-7-(difluoromethoxy)-3,4-dihydro-2H-chromen-2-yl]benzoic Acid (ABBV\/GLPG-2222), a Potent Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Corrector for the Treatment of Cystic Fibrosis","volume":"61","author":"Wang","year":"2018","journal-title":"J. Med. Chem."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1124\/jpet.119.261800","article-title":"Biological Characterization of F508delCFTR Protein Processing by the CFTR Corrector ABBV-2222\/GLPG2222","volume":"372","author":"Singh","year":"2020","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1016\/j.jcf.2019.04.014","article-title":"CFTR activity is enhanced by the novel corrector GLPG2222, given with and without ivacaftor in two randomized trials","volume":"18","author":"Bell","year":"2019","journal-title":"J. Cyst. Fibros."},{"key":"ref_133","unstructured":"(2026, January 19). Sionna Therapeutics Announces First Subjects Dosed in Phase 1 Trial Evaluating NBD1 Stabilizer, SION-451, in Proprietary Dual Combinations in Development for the Treatment of Cystic Fibrosis, 25 August 2025. Available online: https:\/\/investors.sionnatx.com\/news-releases\/news-release-details\/sionna-therapeutics-announces-first-subjects-dosed-phase-1-trial\/."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"S33","DOI":"10.1016\/j.jcf.2025.03.671","article-title":"WS19.01 Stabilizers of CFTR NBD1 synergize with galicaftor (SION-2222) or SION-109 to enable full correction of \u0394F508-CFTR","volume":"24","author":"Hurlbut","year":"2025","journal-title":"J. Cyst. Fibros."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"116120","DOI":"10.1016\/j.ejmech.2023.116120","article-title":"Small molecule modulators of cystic fibrosis transmembrane conductance regulator (CFTR): Structure, classification, and mechanisms","volume":"265","author":"Cao","year":"2024","journal-title":"Eur. J. Med. Chem."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1016\/j.bbrc.2013.12.130","article-title":"S-nitrosothiols increases cystic fibrosis transmembrane regulator expression and maturation in the cell surface","volume":"443","author":"Zaman","year":"2014","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.jcf.2017.01.009","article-title":"Pharmacokinetics and safety of cavosonstat (N91115) in healthy and cystic fibrosis adults homozygous for F508DEL-CFTR","volume":"16","author":"Donaldson","year":"2017","journal-title":"J. Cyst. Fibros."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"9797","DOI":"10.1021\/acs.jmedchem.3c00608","article-title":"Innovative Strategy toward Mutant CFTR Rescue in Cystic Fibrosis: Design and Synthesis of Thiadiazole Inhibitors of the E3 Ligase RNF5","volume":"66","author":"Brusa","year":"2023","journal-title":"J. Med. Chem."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"1892","DOI":"10.1074\/jbc.M308640200","article-title":"Modulation of Mature Cystic Fibrosis Transmembrane Regulator Protein by the PDZ Domain Protein CAL","volume":"279","author":"Cheng","year":"2004","journal-title":"J. Biol. Chem."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"169597","DOI":"10.1016\/j.jmb.2025.169597","article-title":"Sequence Engineering at Non-motif Modulator Residues Yields a Peptide That Effectively Targets a Single PDZ Protein in a Disease-relevant Cellular Context","volume":"438","author":"Amacher","year":"2026","journal-title":"J. Mol. Biol."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1177\/2472555217729790","article-title":"Use of a High-Throughput Phenotypic Screening Strategy to Identify Amplifiers, a Novel Pharmacological Class of Small Molecules That Exhibit Functional Synergy with Potentiators and Correctors","volume":"23","author":"Giuliano","year":"2018","journal-title":"SLAS Discov."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/j.jcf.2020.02.006","article-title":"Amplifiers co-translationally enhance CFTR biosynthesis via PCBP1-mediated regulation of CFTR mRNA","volume":"19","author":"Dukovski","year":"2020","journal-title":"J. Cyst. Fibros."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"17534666251323194","DOI":"10.1177\/17534666251323194","article-title":"Cystic fibrosis: New challenges and perspectives beyond elexacaftor\/tezacaftor\/ivacaftor","volume":"19","author":"Terlizzi","year":"2025","journal-title":"Ther. Adv. Respir. Dis."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/j.jcf.2021.01.009","article-title":"Targeting G542X CFTR nonsense alleles with ELX-02 restores CFTR function in human-derived intestinal organoids","volume":"20","author":"Crawford","year":"2021","journal-title":"J. Cyst. Fibros."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"L756","DOI":"10.1152\/ajplung.00038.2023","article-title":"The synthetic aminoglycoside ELX-02 induces readthrough of G550X-CFTR producing superfunctional protein that can be further enhanced by CFTR modulators","volume":"324","author":"Chen","year":"2023","journal-title":"Am. J. Physiol. Lung Cell Mol. Physiol."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"S28","DOI":"10.1016\/j.jcf.2025.03.573","article-title":"WS14.04Small molecules acting as eRF degraders differently rescue G542X and W1282X-CFTR function","volume":"24","author":"Borrelli","year":"2025","journal-title":"J. Cyst. Fibros."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"3692","DOI":"10.1093\/nar\/gkab194","article-title":"Effect of small molecule eRF3 degraders on premature termination codon readthrough","volume":"49","author":"Balgi","year":"2021","journal-title":"Nucleic Acids Res."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"e154571","DOI":"10.1172\/JCI154571","article-title":"Small-molecule eRF3a degraders rescue CFTR nonsense mutations by promoting premature termination codon readthrough","volume":"132","author":"Lee","year":"2022","journal-title":"J. Clin. Investig."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1164\/rccm.201404-0703OC","article-title":"Clinical Mechanism of the Cystic Fibrosis Transmembrane Conductance Regulator Potentiator Ivacaftor in G551D-mediated Cystic Fibrosis","volume":"190","author":"Rowe","year":"2014","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"106878","DOI":"10.1016\/j.rmed.2022.106878","article-title":"Who are the 10%? Non eligibility of cystic fibrosis (CF) patients for highly effective modulator therapies","volume":"199","author":"Desai","year":"2022","journal-title":"Respir. Med."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1016\/j.jcf.2025.10.007","article-title":"Global prevalence of CFTR variants with respect to their responsiveness to elexacaftor-tezacaftor-ivacaftor","volume":"24","author":"Burgel","year":"2025","journal-title":"J. Cyst. Fibros."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.jcf.2021.10.002","article-title":"Mental status changes during elexacaftor\/tezacaftor \/ ivacaftor therapy","volume":"21","author":"Heo","year":"2022","journal-title":"J. Cyst. Fibros."},{"key":"ref_153","doi-asserted-by":"crossref","unstructured":"Ancel, J., Launois, C., Perotin, J.-M., Ravoninjatovo, B., Mulette, P., Hagenburg, J., Malet, J., Griffon, M., Carr\u00e9, S., and Lebargy, F. (2022). Health-Related Quality of Life in Adults with Cystic Fibrosis: Familial, Occupational, Social, and Mental Health Predictors. Healthcare, 10.","DOI":"10.3390\/healthcare10071351"},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1016\/j.chest.2023.10.043","article-title":"Longitudinal Effects of Elexacaftor\/Tezacaftor\/Ivacaftor: Multidimensional Assessment of Neuropsychological Side Effects and Physical and Mental Health Outcomes in Adolescents and Adults","volume":"165","author":"Graziano","year":"2024","journal-title":"Chest"},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1016\/j.jcf.2022.05.001","article-title":"Dose adjustments of Elexacaftor\/Tezacaftor\/Ivacaftor in response to mental health side effects in adults with cystic fibrosis","volume":"21","author":"Spoletini","year":"2022","journal-title":"J. Cyst. Fibros."},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1001\/jama.1968.03140310070022","article-title":"Dornase aerosol effect on sputum viscosity in cases of cystic fibrosis","volume":"205","author":"Lieberman","year":"1968","journal-title":"JAMA"},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1097\/MCP.0b013e32834b6af4","article-title":"The role of exercise in maintaining health in cystic fibrosis","volume":"17","author":"Dwyer","year":"2011","journal-title":"Curr. Opin. Pulm. Med."},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1378\/chest.121.1.55","article-title":"Long-term benefits of inhaled tobramycin in adolescent patients with cystic fibrosis","volume":"121","author":"Moss","year":"2002","journal-title":"Chest"},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"36","DOI":"10.3310\/nihropenres.13260.1","article-title":"Exploring the nature of perceived treatment burden: A study to compare treatment burden measures in adults with cystic fibrosis","volume":"2","author":"Altabee","year":"2022","journal-title":"NIHR Open Res."},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1080\/08870446.2021.2013483","article-title":"Development and preliminary validation of the challenges of living with cystic fibrosis (CLCF) questionnaire: A 46-item measure of treatment burden for parent\/carers of children with CF","volume":"38","author":"Glasscoe","year":"2023","journal-title":"Psychol. Health"},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.jcf.2024.02.003","article-title":"The effect of discontinuing hypertonic saline or dornase alfa on mucociliary clearance in elexacaftor\/tezacaftor\/ivacaftor treated people with cystic fibrosis: The SIMPLIFY-MCC Study","volume":"23","author":"Donaldson","year":"2024","journal-title":"J. Cyst. Fibros."},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"108464","DOI":"10.1016\/j.rmed.2025.108464","article-title":"Discontinuation of supportive therapies in people with cystic fibrosis treated with elexacaftor\/tezacaftor\/ivacaftor\u2014A patient-reported outcomes\u2019 study","volume":"249","author":"Ahting","year":"2025","journal-title":"Respir. Med."},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/S2213-2600(25)00248-6","article-title":"Effect of elexacaftor\u2013tezacaftor\u2013ivacaftor on bronchial dilatations in adolescents with cystic fibrosis: A multicentre prospective observational study","volume":"14","author":"Letierce","year":"2026","journal-title":"Lancet Respir. Med."},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/S2213-2600(25)00430-8","article-title":"How early should CFTR modulators be initiated to prevent structural cystic fibrosis lung disease?","volume":"14","author":"Woods","year":"2026","journal-title":"Lancet Respir. Med."},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1016\/j.jcf.2025.07.015","article-title":"PRenatal mOdulator treatment to PrEvent CF complicaTions (PROTECT) workshop report","volume":"24","author":"Szentpetery","year":"2025","journal-title":"J. Cyst. Fibros."},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"S37","DOI":"10.1016\/j.jcf.2019.10.020","article-title":"Alternative chloride transport pathways as pharmacological targets for the treatment of cystic fibrosis","volume":"19","author":"Quesada","year":"2020","journal-title":"J. Cyst. Fibros."},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1164\/rccm.201908-1641OC","article-title":"TMEM16A Potentiation: A Novel Therapeutic Approach for the Treatment of Cystic Fibrosis","volume":"201","author":"Danahay","year":"2020","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"167436","DOI":"10.1016\/j.jmb.2021.167436","article-title":"Systems Approaches to Unravel Molecular Function: High-content siRNA Screen Identifies TMEM16A Traffic Regulators as Potential Drug Targets for Cystic Fibrosis","volume":"434","author":"Pinto","year":"2022","journal-title":"J. Mol. Biol."},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"102206","DOI":"10.1016\/j.coph.2022.102206","article-title":"TMEM16A (ANO1) as a therapeutic target in cystic fibrosis","volume":"64","author":"Galietta","year":"2022","journal-title":"Curr. Opin. Pharmacol."},{"key":"ref_170","doi-asserted-by":"crossref","unstructured":"Pinto, M.C., Quaresma, M.C., Silva, I.A.L., Railean, V., Ramalho, S.S., and Amaral, M.D. (2021). Synergy in Cystic Fibrosis Therapies: Targeting SLC26A9. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms222313064"},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1038\/s41467-017-00813-z","article-title":"MicroRNA-9 downregulates the ANO1 chloride channel and contributes to cystic fibrosis lung pathology","volume":"8","author":"Sonneville","year":"2017","journal-title":"Nat. Commun."},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"6463","DOI":"10.1016\/j.ymthe.2025.08.045","article-title":"Restoring chloride efflux in cystic fibrosis with TMEM16a antisense oligonucleotides","volume":"33","author":"Mitri","year":"2025","journal-title":"Mol. Ther."},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"16354","DOI":"10.1073\/pnas.1214596109","article-title":"Calcium-activated chloride channel TMEM16A modulates mucin secretion and airway smooth muscle contraction","volume":"109","author":"Huang","year":"2012","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"4502","DOI":"10.1096\/fj.201801333RRR","article-title":"TMEM16A is indispensable for basal mucus secretion in airways and intestine","volume":"33","author":"Benedetto","year":"2019","journal-title":"FASEB J."},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1038\/s41525-022-00299-9","article-title":"Genetic evidence supports the development of SLC26A9 targeting therapies for the treatment of lung disease","volume":"7","author":"Gong","year":"2022","journal-title":"npj Genom. Med."},{"key":"ref_176","doi-asserted-by":"crossref","unstructured":"Gorrieri, G., Zara, F., and Scudieri, P. (2022). SLC26A9 as a Potential Modifier and Therapeutic Target in Cystic Fibrosis Lung Disease. Biomolecules, 12.","DOI":"10.3390\/biom12020202"},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1038\/s41586-019-1018-5","article-title":"Small-molecule ion channels increase host defences in cystic fibrosis airway epithelia","volume":"567","author":"Muraglia","year":"2019","journal-title":"Nature"},{"key":"ref_178","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/j.jcf.2020.11.018","article-title":"Amphotericin B induces epithelial voltage responses in people with cystic fibrosis","volume":"20","author":"Chorghade","year":"2021","journal-title":"J. Cyst. Fibros."},{"key":"ref_179","doi-asserted-by":"crossref","first-page":"2608","DOI":"10.1038\/s41598-018-20708-3","article-title":"Small molecule anionophores promote transmembrane anion permeation matching CFTR activity","volume":"8","author":"Hernando","year":"2018","journal-title":"Sci. Rep."},{"key":"ref_180","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.jcf.2024.06.002","article-title":"ETD001: A novel inhaled ENaC blocker with an extended duration of action in vivo","volume":"24","author":"Danahay","year":"2025","journal-title":"J. Cyst. Fibros."},{"key":"ref_181","doi-asserted-by":"crossref","first-page":"00986","DOI":"10.1183\/23120541.00986-2023","article-title":"Randomised, phase 1\/2a trial of ION-827359, an antisense oligonucleotide inhibitor of ENaC","volume":"10","author":"Sutharsan","year":"2024","journal-title":"ERJ Open Res."},{"key":"ref_182","doi-asserted-by":"crossref","first-page":"116038","DOI":"10.1016\/j.ejmech.2023.116038","article-title":"Discovery and development of BI 1265162, an ENaC inhibitor for the treatment of cystic fibrosis","volume":"265","author":"Betzemeier","year":"2024","journal-title":"Eur. J. Med. Chem."},{"key":"ref_183","doi-asserted-by":"crossref","first-page":"2000946","DOI":"10.1183\/13993003.00946-2020","article-title":"ENaC inhibition in cystic fibrosis: Potential role in the new era of CFTR modulator therapies","volume":"56","author":"Mall","year":"2020","journal-title":"Eur. Respir. J."},{"key":"ref_184","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1007\/s00424-018-2160-x","article-title":"Expression and function of Anoctamin 1\/TMEM16A calcium-activated chloride channels in airways of in vivo mouse models for cystic fibrosis research","volume":"470","author":"Hahn","year":"2018","journal-title":"Pflug. Arch."},{"key":"ref_185","doi-asserted-by":"crossref","first-page":"2100746","DOI":"10.1183\/13993003.00746-2021","article-title":"Efficacy and safety of inhaled ENaC inhibitor BI 1265162 in patients with cystic fibrosis: BALANCE-CF 1, a randomised, phase II study","volume":"59","author":"Goss","year":"2022","journal-title":"Eur. Respir. J."},{"key":"ref_186","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.jcf.2025.11.015","article-title":"ETD001, a long-acting inhaled ENaC blocker, is well tolerated in a first human, healthy participant trial","volume":"25","author":"Russell","year":"2026","journal-title":"J. Cyst. Fibros."},{"key":"ref_187","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/j.jcf.2019.06.010","article-title":"Theranostics by testing CFTR modulators in patient-derived materials: The current status and a proposal for subjects with rare CFTR mutations","volume":"18","author":"Amaral","year":"2019","journal-title":"J. Cyst. Fibros."},{"key":"ref_188","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1016\/j.celrep.2019.01.068","article-title":"Rectal Organoids Enable Personalized Treatment of Cystic Fibrosis","volume":"26","author":"Berkers","year":"2019","journal-title":"Cell Rep."},{"key":"ref_189","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1016\/S2213-2600(24)00208-X","article-title":"The expanded French compassionate programme for elexacaftor-tezacaftor-ivacaftor use in people with cystic fibrosis without a F508del CFTR variant: A real-world study","volume":"12","author":"Burgel","year":"2024","journal-title":"Lancet Respir. Med."},{"key":"ref_190","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1016\/S2213-2600(25)00190-0","article-title":"Sweat chloride and lung function responses to elexacaftor-tezacaftor-ivacaftor in people with cystic fibrosis with two versus one responsive CFTR variants: An analysis of two real-world observational studies","volume":"13","author":"Burgel","year":"2025","journal-title":"Lancet Respir. Med."},{"key":"ref_191","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/j.jcf.2025.08.011","article-title":"Correlation between patient-derived intestinal organoids and clinical responses to CFTR modulators in people with cystic fibrosis homozygous for F508del","volume":"24","author":"Cuyx","year":"2025","journal-title":"J. Cyst. Fibros."},{"key":"ref_192","doi-asserted-by":"crossref","first-page":"344ra84","DOI":"10.1126\/scitranslmed.aad8278","article-title":"Characterizing responses to CFTR-modulating drugs using rectal organoids derived from subjects with cystic fibrosis","volume":"8","author":"Dekkers","year":"2016","journal-title":"Sci. Transl. Med."},{"key":"ref_193","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/s41231-020-00060-3","article-title":"Rationale and design of the HIT-CF organoid study: Stratifying cystic fibrosis patients based on intestinal organoid response to different CFTR-modulators","volume":"5","author":"Michel","year":"2020","journal-title":"Transl. Med. Commun."},{"key":"ref_194","doi-asserted-by":"crossref","first-page":"1902426","DOI":"10.1183\/13993003.02426-2019","article-title":"Correction of CFTR function in intestinal organoids to guide treatment of cystic fibrosis","volume":"57","author":"Ramalho","year":"2021","journal-title":"Eur. Respir. J."},{"key":"ref_195","doi-asserted-by":"crossref","first-page":"2401855","DOI":"10.1183\/13993003.01855-2024","article-title":"Relationship between theratyping in nasal epithelial cells and clinical outcomes in people with cystic fibrosis","volume":"65","author":"Ratjen","year":"2025","journal-title":"Eur. Respir. J."},{"key":"ref_196","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.jcf.2024.09.013","article-title":"Theranostics vs theratyping or theranostics plus theratyping?","volume":"24","author":"Amaral","year":"2025","journal-title":"J. Cyst. Fibros."},{"key":"ref_197","doi-asserted-by":"crossref","first-page":"C866","DOI":"10.1152\/ajpcell.00404.2009","article-title":"Influence of cell background on pharmacological rescue of mutant CFTR","volume":"298","author":"Pedemonte","year":"2010","journal-title":"Am. J. Physiol. Cell Physiol."},{"key":"ref_198","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.jcf.2018.05.004","article-title":"CFTR modulator theratyping: Current status, gaps and future directions","volume":"18","author":"Clancy","year":"2019","journal-title":"J. Cyst. Fibros."},{"key":"ref_199","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1016\/j.jcf.2024.02.006","article-title":"In vitro modulator responsiveness of 655 CFTR variants found in people with cystic fibrosis","volume":"23","author":"Bihler","year":"2024","journal-title":"J. Cyst. Fibros."},{"key":"ref_200","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s10719-024-10174-7","article-title":"Effect of CFTR modulators Elexacaftor\/Tezacaftor\/Ivacaftor on lipid metabolism in human bronchial epithelial cells","volume":"42","author":"Dobi","year":"2025","journal-title":"Glycoconj. J."},{"key":"ref_201","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.jconrel.2019.01.025","article-title":"Inhalation treatment of cystic fibrosis with lumacaftor and ivacaftor co-delivered by nanostructured lipid carriers","volume":"296","author":"Garbuzenko","year":"2019","journal-title":"J. Control. Release"},{"key":"ref_202","doi-asserted-by":"crossref","first-page":"126124","DOI":"10.1016\/j.ijpharm.2025.126124","article-title":"Pulmonary targeted delivery of ivacaftor liposomes for F508 del-CFTR mutation mediated cystic fibrosis therapy","volume":"684","author":"Anjum","year":"2025","journal-title":"Int. J. Pharm."},{"key":"ref_203","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.jconrel.2024.07.011","article-title":"Lipid nanoparticle-mediated hepatocyte delivery of siRNA and silibinin in metabolic dysfunction-associated steatotic liver disease","volume":"373","author":"Lyu","year":"2024","journal-title":"J. Control. Release"},{"key":"ref_204","doi-asserted-by":"crossref","first-page":"2463428","DOI":"10.1080\/10717544.2025.2463428","article-title":"Impact of nebulizers on nanoparticles-based gene delivery efficiency: In vitro and in vivo comparison of jet and mesh nebulizers using branched-polyethyleneimine","volume":"32","author":"Ghanem","year":"2025","journal-title":"Drug Deliv."},{"key":"ref_205","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1016\/j.jcf.2022.04.007","article-title":"Current prices versus minimum costs of production for CFTR modulators","volume":"21","author":"Guo","year":"2022","journal-title":"J. Cyst. Fibros."},{"key":"ref_206","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1038\/s41434-023-00390-5","article-title":"Successes and challenges in clinical gene therapy","volume":"30","author":"Kohn","year":"2023","journal-title":"Gene Ther."},{"key":"ref_207","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1038\/s41434-023-00402-4","article-title":"Approval and therapeutic value of gene therapies in the US and Europe","volume":"30","author":"Vokinger","year":"2023","journal-title":"Gene Ther."}],"container-title":["Pharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4923\/18\/8\/1040\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T04:13:08Z","timestamp":1787458388000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4923\/18\/8\/1040"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,21]]},"references-count":207,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2026,8]]}},"alternative-id":["pharmaceutics18081040"],"URL":"https:\/\/doi.org\/10.3390\/pharmaceutics18081040","relation":{},"ISSN":["1999-4923"],"issn-type":[{"value":"1999-4923","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,21]]}}}